In March of 2017, we
announced that our deep learning based digital breast tomosynthesis (DBT) solution
– PowerLook
Tomo Detection – had received approval from the U.S. Food and Drug Administration
(FDA). For those not familiar, PowerLook Tomo Detection is a first-of-its-kind, concurrent-read computer aided
detection solution designed to assist radiologists in reading DBT studies. As part of the development for the
product, PowerLook Tomo went through a reader study where it showed time
savings of 29.2% for a radiologist when reading large data sets without
impacting radiologist clinical performance.
Flash forward a year later and our solution has not only
been adopted by healthcare organizations worldwide, but has also just been
named a finalist for the 2018 Medical Design Excellence Awards (MDEA), the
premier awards program for the medtech industry! The MDEA recognizes the technological achievements of
medical device manufacturers that work toward improving the quality of
healthcare delivery and accessibility.
Out of hundreds of submissions, we are honored to be named a
finalist. In June, our team will be traveling to New York City where the winners
will be announced on stage at the MDEA ceremony. The winners are chosen by an
impartial panel of judges comprised of clinicians, engineers and designers with
years of experience in the industry. Judgement is based on five criteria,
including design and engineering innovations, functional innovations, benefits
to overall healthcare, benefits to patients and competitive landscape.
We are honored to have been named a finalist and
look forward to networking with our peers at the ceremony in June. Stay
tuned for future updates on the results of the MDEA awards and other
exciting news to come!
About iCAD:
iCAD is a global medical technology leader providing innovative cancer detection and therapy solutions. We work passionately to provide precise, powerful healthcare solutions expertly engineered to optimize operational efficiency, clinician confidence and patient outcomes. iCAD offers a comprehensive range of artificial intelligence and workflow solutions to support rapid and accurate detection of breast and colorectal cancers. For more information, visit www.icadmed.com or www.xoftinc.com.